Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides

Frontiers in Cellular Neuroscience

Volumn 8, Issue JAN, 2015, Pages

  Moutal, Aubin ^a   François Moutal, Liberty ^a   Brittain, Joel M ^b,c   Khanna, May ^a   Khanna, Rajesh ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cell penetrating peptide; CRMP2; Delayed calcium dysregulation; Excitotoxicity; Neuroprotection; NMDAR

Indexed keywords

CELL PENETRATING PEPTIDE; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOTINYLATION; CONTROLLED STUDY; ENZYME ACTIVATION; FLUORESCENCE; FLUORESCENCE MICROSCOPY; IMAGE ANALYSIS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LONG TERM POTENTIATION; MEMBRANE VESICLE; NEUROPROTECTION; NONHUMAN; PINOCYTOSIS; RAT;

EID: 84937549237     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00471     Document Type: Article

References (61)

1. Al-Hallaq, R. A., Conrads, T. P., Veenstra, T. D., and Wenthold, R. J. (2007). NMDA di-heteromeric receptor populations and associated proteins in rat hippocampus. J. Neurosci. 27, 8334-8343. doi: 10. 1523/jneurosci. 2155-07. 2007.
2. Arimura, N., Ménager, C., Kawano, Y., Yoshimura, T., Kawabata, S., Hattori, A., et al. (2005). Phosphorylation by Rho kinase regulates CRMP-2 activity in growth cones. Mol. Cell. Biol. 25, 9973-9984. doi: 10. 1128/mcb. 25. 22. 9973-9984. 2005.
3. Auberson, Y. P., Allgeier, H., Bischoff, S., Lingenhoehl, K., Moretti, R., and Schmutz, M. (2002). 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg. Med. Chem. Lett. 12, 1099-1102. doi: 10. 1016/s0960-894x(02)00074-4.
4. Bauer, B., Davidson, M., and Orwar, O. (2009). Proteomic analysis of plasma membrane vesicles. Angew. Chem. Int. Ed. Engl. 48, 1656-1659. doi: 10. 1002/anie. 200803898.
5. Bretin, S., Rogemond, V., Marin, P., Maus, M., Torrens, Y., Honnorat, J., et al. (2006). Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. J. Neurochem. 98, 1252-1265. doi: 10. 1111/j. 1471-4159. 2006. 03969. x.
6. Brittain, J. M., Chen, L., Wilson, S. M., Brustovetsky, T., Gao, X., Ashpole, N. M., et al. (2011a). Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2). J. Biol. Chem. 286, 37778-37792. doi: 10. 1074/jbc. M111. 255455.
7. Brittain, J. M., Duarte, D. B., Wilson, S. M., Zhu, W., Ballard, C., Johnson, P. L., et al. (2011b). Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca2+ channel complex. Nat. Med. 17, 822-829. doi: 10. 1038/nm. 2345.
8. Brittain, J. M., Pan, R., You, H., Brustovetsky, T., Brustovetsky, N., Zamponi, G. W., et al. (2012). Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model. Channels (Austin) 6, 52-59. doi: 10. 4161/chan. 18919.
9. Brittain, J. M., Piekarz, A. D., Wang, Y., Kondo, T., Cummins, T. R., and Khanna, R. (2009). An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels. J. Biol. Chem. 284, 31375-31390. doi: 10. 1074/jbc. m109. 009951.
10. Brugnano, J., Ward, B. C., and Panitch, A. (2010). Cell penetrating peptides can exert biological activity: a review. Biomol. Concepts 1, 109-116. doi: 10. 1515/bmc. 2010. 016.
11. Brustovetsky, T., Pellman, J. J., Yang, X. F., Khanna, R., and Brustovetsky, N. (2014). Collapsin response mediator protein 2 (CRMP2) interacts with N-methyl-D-aspartate (NMDA) receptor and Na+/Ca2+ exchanger and regulates their functional activity. J. Biol. Chem. 289, 7470-7482. doi: 10. 1074/jbc. m113. 518472.
12. Cameron, A., Appel, J., Houghten, R. A., and Lindberg, I. (2000). Polyarginines are potent furin inhibitors. J. Biol. Chem. 275, 36741-36749. doi: 10. 1074/jbc. m003848200.
13. Charras, G. T., Yarrow, J. C., Horton, M. A., Mahadevan, L., and Mitchison, T. J. (2005). Non-equilibration of hydrostatic pressure in blebbing cells. Nature 435, 365-369. doi: 10. 1038/nature03550.
14. Chung, M. A., Lee, J. E., Lee, J. Y., Ko, M. J., Lee, S. T., and Kim, H. J. (2005). Alteration of collapsin response mediator protein-2 expression in focal ischemic rat brain. Neuroreport 16, 1647-1653. doi: 10. 1097/01. wnr. 0000176520. 49841. e6.
15. Duchardt, F., Fotin-Mleczek, M., Schwarz, H., Fischer, R., and Brock, R. (2007). A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8, 848-866. doi: 10. 1111/j. 1600-0854. 2007. 00572. x.
16. Faden, A. I., Demediuk, P., Panter, S. S., and Vink, R. (1989). The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244, 798-800. doi: 10. 1126/science. 2567056.
17. Fridriksson, E. K., Shipkova, P. A., Sheets, E. D., Holowka, D., Baird, B., and McLafferty, F. W. (1999). Quantitative analysis of phospholipids in functionally important membrane domains from RBL-2H3 mast cells using tandem high-resolution mass spectrometry. Biochemistry 38, 8056-8063. doi: 10. 1021/bi9828324.
18. Fugere, M., Appel, J., Houghten, R. A., Lindberg, I., and Day, R. (2007). Short polybasic peptide sequences are potent inhibitors of PC5/6 and PC7: use of positional scanning-synthetic peptide combinatorial libraries as a tool for the optimization of inhibitory sequences. Mol. Pharmacol. 71, 323-332. doi: 10. 1124/mol. 106. 027946.
19. Gillessen, T., Budd, S. L., and Lipton, S. A. (2002). Excitatory amino acid neurotoxicity. Adv. Exp. Med. Biol. 513, 3-40.
20. Goshima, Y., Nakamura, F., Strittmatter, P., and Strittmatter, S. M. (1995). Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature 376, 509-514. doi: 10. 1038/376509a0.
21. Grotta, J. C., Picone, C. M., Ostrow, P. T., Strong, R. A., Earls, R. M., Yao, L. P., et al. (1990). CGS-19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann. Neurol. 27, 612-619. doi: 10. 1002/ana. 410270605.
22. Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405-414. doi: 10. 1038/nn835.
23. Horn, M., Pavlík, M., Dolecková, L., Baudys, M., and Mares, M. (2000). Arginine-based structures are specific inhibitors of cathepsin, C. Application of peptide combinatorial libraries. Eur. J. Biochem. 267, 3330-3336. doi: 10. 1046/j. 1432-1327. 2000. 01364. x.
24. Hou, S. T., Jiang, S. X., Aylsworth, A., Ferguson, G., Slinn, J., Hu, H., et al. (2009). CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. J. Neurochem. 111, 870-881. doi: 10. 1111/j. 1471-4159. 2009. 06375. x.
25. Ikonomidou, C., Stefovska, V., and Turski, L. (2000). Neuronal death enhanced by N-methyl-D-aspartate antagonists. Proc. Natl. Acad. Sci. U S A 97, 12885-12890. doi: 10. 1073/pnas. 220412197.
26. Ikonomidou, C., and Turski, L. (2002). Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 1, 383-386. doi: 10. 1016/s1474-4422(02)00164-3.
27. Jiang, S. X., Kappler, J., Zurakowski, B., Desbois, A., Aylsworth, A., and Hou, S. T. (2007). Calpain cleavage of collapsin response mediator proteins in ischemic mouse brain. Eur. J. Neurosci. 26, 801-809. doi: 10. 1111/j. 1460-9568. 2007. 05715. x.
28. Jin, L., Millard, A. C., Wuskell, J. P., Clark, H. A., and Loew, L. M. (2005). Cholesterol-enriched lipid domains can be visualized by di-4-ANEPPDHQ with linear and nonlinear optics. Biophys. J. 89, L04-L06. doi: 10. 1529/biophysj. 105. 064816.
29. Kilk, K., Mahlapuu, R., Soomets, U., and Langel, U. (2009). Analysis of in vitro toxicity of five cell-penetrating peptides by metabolic profiling. Toxicology 265, 87-95. doi: 10. 1016/j. tox. 2009. 09. 016.
30. Kloss, A., Henklein, P., Siele, D., Schmolke, M., Apcher, S., Kuehn, L., et al. (2009). The cell-penetrating peptide octa-arginine is a potent inhibitor of proteasome activities. Eur. J. Pharm. Biopharm. 72, 219-225. doi: 10. 1016/j. ejpb. 2008. 10. 016.
31. Kuo, J. H., Jan, M. S., Lin, Y. L., and Lin, C. (2009). Interactions between octaarginine and U-937 human macrophages: global gene expression profiling, superoxide anion content and cytokine production. J. Control. Release 139, 197-204. doi: 10. 1016/j. jconrel. 2009. 07. 006.
32. Lau, A., and Tymianski, M. (2010). Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 460, 525-542. doi: 10. 1007/s00424-010-0809-1.
33. Lin, Y. Z., Yao, S. Y., Veach, R. A., Torgerson, T. R., and Hawiger, J. (1995). Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 270, 14255-14258. doi: 10. 1074/jbc. 270. 24. 14255.
34. Liu, Y., Wong, T. P., Aarts, M., Rooyakkers, A., Liu, L., Lai, T. W., et al. (2007). NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J. Neurosci. 27, 2846-2857. doi: 10. 1523/jneurosci. 0116-07. 2007.
35. Madani, F., Lindberg, S., Langel, U., Futaki, S., and Gräslund, A. (2011). Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys. 2011: 414729. doi: 10. 1155/2011/414729.
36. Maniti, O., Piao, H. R., and Ayala-Sanmartin, J. (2014). Basic cell penetrating peptides induce plasma membrane positive curvature, lipid domain separation and protein redistribution. Int. J. Biochem. Cell Biol. 50, 73-81. doi: 10. 1016/j. biocel. 2014. 02. 017.
37. Mizuta, I., Katayama, M., Watanabe, M., Mishina, M., and Ishii, K. (1998). Developmental expression of NMDA receptor subunits and the emergence of glutamate neurotoxicity in primary cultures of murine cerebral cortical neurons. Cell. Mol. Life Sci. 54, 721-725. doi: 10. 1007/s000180050199.
38. Muir, K. W. (2006). Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr. Opin. Pharmacol. 6, 53-60. doi: 10. 1016/j. coph. 2005. 12. 002.
39. Nicholls, D. G. (2004). Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr. Mol. Med. 4, 149-177. doi: 10. 2174/1566524043479239.
40. Oehlke, J., Scheller, A., Wiesner, B., Krause, E., Beyermann, M., Klauschenz, E., et al. (1998). Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta 1414, 127-139. doi: 10. 1016/s0005-2736(98)00161-8.
41. Piekarz, A. D., Due, M. R., Khanna, M., Wang, B., Ripsch, M. S., Wang, R., et al. (2012). CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy. Mol. Pain 8: 54. doi: 10. 1186/1744-8069-8-54.
42. Ripsch, M. S., Ballard, C. J., Khanna, M., Hurley, J. H., White, F. A., and Khanna, R. (2012). A peptide uncoupling CRMP-2 from the presynaptic Ca(2+) channel complex demonstrates efficacy in animal models of migraine and AIDS therapy-induced neuropathy. Transl. Neurosci. 3, 1-8. doi: 10. 2478/s13380-012-0002-4.
43. Rogemond, V., Auger, C., Giraudon, P., Becchi, M., Auvergnon, N., Belin, M. F., et al. (2008). Processing and nuclear localization of CRMP2 during brain development induce neurite outgrowth inhibition. J. Biol. Chem. 283, 14751-14761. doi: 10. 1074/jbc. M708480200.
44. Saalik, P., Niinep, A., Pae, J., Hansen, M., Lubenets, D., Langel, U., et al. (2011). Penetration without cells: membrane translocation of cell-penetrating peptides in the model giant plasma membrane vesicles. J. Control. Release 153, 117-125. doi: 10. 1016/j. jconrel. 2011. 03. 011.
45. Sarko, D., Beijer, B., Garcia Boy, R., Nothelfer, E. M., Leotta, K., Eisenhut, M., et al. (2010). The pharmacokinetics of cell-penetrating peptides. Mol. Pharm. 7, 2224-2231. doi: 10. 1021/mp100223d.
46. Sawant, R. S., Patel, N. R., and Torchilin, V. P. (2013). Therapeutic delivery using cell-penetrating peptides. Eur. J. Nanomed. 5, 141-158. doi: 10. 1515/ejnm-2013-0005.
47. Sezgin, E., Kaiser, H. J., Baumgart, T., Schwille, P., Simons, K., and Levental, I. (2012). Elucidating membrane structure and protein behavior using giant plasma membrane vesicles. Nat. Protoc. 7, 1042-1051. doi: 10. 1038/nprot. 2012. 059.
48. Stanika, R. I., Pivovarova, N. B., Brantner, C. A., Watts, C. A., Winters, C. A., and Andrews, S. B. (2009). Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc. Natl. Acad. Sci. U S A 106, 9854-9859. doi: 10. 1073/pnas. 0903546106.
49. Steinberg, G. K., Panahian, N., Perez-Pinzon, M. A., Sun, G. H., Modi, M. W., and Sepinwall, J. (1995). Narrow temporal therapeutic window for NMDA antagonist protection against focal cerebral ischaemia. Neurobiol. Dis. 2, 109-118. doi: 10. 1006/nbdi. 1995. 0011.
50. Tahimic, C. G., Tomimatsu, N., Nishigaki, R., Fukuhara, A., Toda, T., Kaibuchi, K., et al. (2006). Evidence for a role of Collapsin response mediator protein-2 in signaling pathways that regulate the proliferation of non-neuronal cells. Biochem. Biophys. Res. Commun. 340, 1244-1250. doi: 10. 1016/j. bbrc. 2005. 12. 132.
51. Touma, E., Kato, S., Fukui, K., and Koike, T. (2007). Calpain-mediated cleavage of collapsin response mediator protein(CRMP)-2 during neurite degeneration in mice. Eur. J. Neurosci. 26, 3368-3381. doi: 10. 1111/j. 1460-9568. 2007. 05943. x.
52. Ward, B., Seal, B. L., Brophy, C. M., and Panitch, A. (2009). Design of a bioactive cell-penetrating peptide: when a transduction domain does more than transduce. J. Pept. Sci. 15, 668-674. doi: 10. 1002/psc. 1168.
53. Wender, P. A., Mitchell, D. J., Pattabiraman, K., Pelkey, E. T., Steinman, L., and Rothbard, J. B. (2000). The design, synthesis and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U S A 97, 13003-13008. doi: 10. 1073/pnas. 97. 24. 13003.
54. Williams, K. (1993). Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol. Pharmacol. 44, 851-859.
55. Wilson, S. M., Brittain, J. M., Piekarz, A. D., Ballard, C. J., Ripsch, M. S., Cummins, T. R., et al. (2011). Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex. Channels (Austin) 5, 449-456. doi: 10. 4161/chan. 5. 5. 17363.
56. Wilson, S. M., Schmutzler, B. S., Brittain, J. M., Dustrude, E. T., Ripsch, M. S., Pellman, J. J., et al. (2012). Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides. J. Biol. Chem. 287, 35065-35077. doi: 10. 1074/jbc. M112. 378695.
57. Xiong, T., Tang, J., Zhao, J., Chen, H., Zhao, F., Li, J., et al. (2012). Involvement of the Akt/GSK-3beta/CRMP-2 pathway in axonal injury after hypoxic-ischemic brain damage in neonatal rat. Neuroscience 216, 123-132. doi: 10. 1016/j. neuroscience. 2012. 04. 052.
58. Yin, Y., Wang, Y., Chen, L., Han, S., Zhao, L., Luo, Y., et al. (2013). Tat-collapsin response mediator protein 2 (CRMP2) increases the survival of neurons after NMDA excitotoxity by reducing the cleavage of CRMP2. Neurochem. Res. 38, 2095-2104. doi: 10. 1007/s11064-013-1118-9.
59. Zaro, J. L., Vekich, J. E., Tran, T., and Shen, W. C. (2009). Nuclear localization of cell-penetrating peptides is dependent on endocytosis rather than cytosolic delivery in CHO cells. Mol. Pharm. 6, 337-344. doi: 10. 1021/mp800239p.
60. Zhang, Z., Majava, V., Greffier, A., Hayes, R. L., Kursula, P., and Wang, K. K. (2009). Collapsin response mediator protein-2 is a calmodulin-binding protein. Cell. Mol. Life Sci. 66, 526-536. doi: 10. 1007/s00018-008-8362-1.
61. Zhou, M., and Baudry, M. (2006). Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J. Neurosci. 26, 2956-2963. doi: 10. 1523/jneurosci. 4299-05. 2006.